Biomarcadors i Mecanismes Moleculars de Malalties (DIBIOMEC)

ONCOLOGIA
OBJECTIUS

Sobre DIBIOMEC

Fundat el 2016, el grup de recerca de Biomarcadors de Malalties i Mecanismes Moleculars (DIBIOMEC) opera sota l’Institut de Recerca Biomèdica Catalunya Sud (IRB CatSud) i l’Hospital Universitari Joan XXIII de Tarragona (HJ23). Reconegut com a grup de recerca consolidat per l’Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de la Universitat Rovira i Virgili, estem compromesos amb l’avenç en el coneixement de biomarcadors en malalties relacionades amb la inflamació.

 

En què ens centrem

Els nostres principals esforços de recerca es dediquen a la identificació de biomarcadors per al diagnòstic i el pronòstic de malalties, en particular les relacionades amb la inflamació. Ens centrem en el microentorn del càncer, inclosos els microARN associats a exosomes, i explorem els seus gens diana com a possibles dianes terapèutiques. El nostre objectiu és traduir els descobriments de laboratori en aplicacions clíniques, tendint un pont entre el laboratori i el pacient.

El nostre equip multidisciplinari, que inclou uròlegs, patòlegs i científics bàsics, col·labora estretament per abordar qüestions clínicament rellevants a través de la investigació biològica. Utilitzem un flux de treball que integra dades derivades de pacients amb experiments in vitro, amb l’objectiu de descobrir biomarcadors per a ús clínic i dilucidar-ne els mecanismes moleculars d’acció.

RESPONSABLES
  • Dra. Matilde Rodríguez Chacón

  • Dr. Xavier Ruiz Plazas

  • Línies de recerca
  • Patents
  • Membres del grup
  • Difusió
  • Publicacions
  • Projectes
  • Contacte
  • El teixit adipós peritumoral en l’agressivitat del càncer
    Investigació del paper del teixit adipós peritumoral en l’agressivitat del càncer.
  • Caracterització del microentorn del càncer en la cerca de nous biomarcadors
    Exploració del microambient tumoral per descobrir nous biomarcadors per al diagnòstic i el pronòstic del càncer.

  • INVENTORS: Matilde Rodríguez Chacón, Xavier Ruiz Plazas, Josep Segarra Tomás, Joan Francesc García Fontgivell, Salomé Martínez González, Javier Lozano Bartolomé.

    TÍTLE: Biomarcadors d’agressivitat de càncer de pròstata

    No: EP18382842.5

    APPLICATION DATE: 22/11/2018

    INSTITUTION: Institut d’Investigació Sanitària Pere Virgili (IISPV)

  • INVENTORS: Matilde Rodríguez Chacón, Xavier Ruiz Plazas, Josep Segarra Tomás, Joan Francesc García Fontgivell, Salomé Martínez González, Javier Lozano Bartolomé, Antón Altuna-Coy.

    TÍTLE: biomarkers of prostate cancer aggressiveness

    No: PCT/EP2019/082081

    APPLICATION DATE: 22/11/2019

    INSTITUTION: Institut d’Investigació Sanitària Pere Virgili (IISPV)

    https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020104588&tab=PCTDOCUMENTS

  • INVENTORS: Rodriguez Chacón, M; Ruiz Plazas, X; Segarra Tomas, J; Garcia Fontgivell, JF; Altuna Coy,A; Bernal Escoté, X; Arreaza Gil, V; Alves Santiago, M.

    TITLE: Algorithm DiPrAS-CaP

    Ref. i-DEPOT: 145575

    APPLICATION DATE: 19-02-2024

    Expiry date: 19-02-2029.

  • INVENTORS: M. Rodriguez Chacón, X. Ruiz Plazas, J. Segarra Tomas, J. F. Garcia Fontgivell, A. Altuna Coy, X. Bernal Escoté, V, Arreaza Gil

    TITLE: Improved Method For Prostate Cancer Prognosis For Patients Under Active Surveillance

    No: EP 243824596

    DATE: 25/04/2024

    Periprostatic adipose tissue-derived extracellular vesicles modulate prostate cancer cell behaviour in vitro according to tumour grade.

    Arreaza-Gil V, Altamirano GA, Altuna-Coy A, Moreno-Lanceta A, Sánchez-Martin S, Diaz-Valdivia N, Alcaraz J, Escoté XB, Garcia-Fontgivell JF, Ascaso-Til H, Segarra-Tomás J, Ruiz-Plazas X, Chacón MR. 21/01/2026

    A Semen Panel Signature Comprising sTWEAK Cytokine Levels and Expression of exomiR-221-3p and exomiR-222-3p for Assessing Prostate Cancer Prognosis, Diagnostic Utility, and Detection of Upgrading During Active Surveillance.

    Alves-Santiago M, Altuna-Coy A, López-Ribelles P, Arreaza-Gil V, Segarra-Tomás J, Ascaso-Til H, Garcia-Fontgivell JF, Sánchez-Martín S, Bernal-Escoté X, Ruiz-Plazas X, Chacón MR. 01/01/2026

    Reply by Authors.

    Alves-Santiago M, Altuna-Coy A, López-Ribelles P, Arreaza-Gil V, Segarra-Tomás J, Ascaso-Til H, Garcia-Fontgivell JF, Sánchez-Martín S, Bernal-Escoté X, Ruiz-Plazas X, Chacón MR. 01/01/2026

    Developing a Predictive Model for Significant Prostate Cancer Detection in Prostatic Biopsies from Seven Clinical Variables: Is Machine Learning Superior to Logistic Regression?

    Morote J, Miró B, Hernando P, Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, Celma A, García-de Manuel G, Servian P, Abascal JM, Trilla E, Méndez O. 25/03/2025

    Efficacy of Prostate Biopsies via Transperineal and Transrectal Routes for Significant Prostate Cancer Detection: A Multicenter Paired-Matched Study.

    Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, Celma A, García-de Manuel G, Miró B, Servian P, Abascal JM, Trilla E, Morote J. 26/01/2025

    The Role of Digital Rectal Examination for Early Detection of Significant Prostate Cancer in the Era of Magnetic Resonance Imaging

    Morote, J, Paesano, N, Picola, N, Muñoz-Rodriguez, J, Ruiz-Plazas, X, Muñoz-Rivero, MV, Celma, A, Manuel, GGD, Miró, B, Abascal, JM, Servian, P, Méndez, O, Trilla, E. 01/11/2024

    Photoperiod effects on corticosterone and seasonal clocks in cafeteria-induced obese fischer 344 rats are influenced by gut microbiota

    Arreaza-Gil, V, Escobar-Martínez, I, Soliz-Rueda, JR, Suárez, M, Muguerza, B, Schellekens, H, Torres-Fuentes, C, Arola-Arnal, A. 29/09/2024

    Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with transperineal prostate biopsies

    Morote, J, Paesano, N, Picola, N, Muñoz-Rodriguez, J, Muñoz-Rivero, M, Ruiz-Plazas, X, Celma, A, García-de Manuel, GGD, Miró, B, Servian, P, Abascal, JM. 01/09/2024

    Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain

    Molina, MRG, Huertas, CM, Joven-Ibanez, B, de Prado, L, Mateo, L, Gomez, ML, del Rio, AH, Blanco-Morales, EA, Calzada, JM, Lizarzaburu, MS, Ros-Vilamajo, I, Steiner, M, Perez, EC, Hern ndez-Hern ndez, V, Oreiro, SC, Urruticoechea, A, Palacio, LO, Esteban, JC, Gonz lez, RV, Alc zar, OC, Moreno-Gil, MP, Diez, AA, Moreno-Ramos, MJ, Pan, FJM, D az-Castroverde, S, Fern ndez, SM, Tasende, JAP, Garc a, JR. 01/09/2024

    PERSISTENCE OF SEQUENCING GUSELKUMAB OR TNFI AS A SECOND-LINE THERAPY FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN REAL WORLD PRACTICE IN SPAIN - MANHATTAN STUDY

    Díaz, LM, Molin, RG, Huertas, CM, Joven-Ibáñez, B, Fernández-Nebro, A, Casares, EG, Soria, LM, del Río, AH, Blanco-Morales, EA, Calzada, JM, Lizarzaburu, MS, Vilamajó, IR, Pérez, ECC, Hernández-Hernández, V, Oreiro, SC, Arana, AU, Palacio, LO, Esteban, JC, González, RV, Alcazar, OC, Moreno-Gil, MP, Díez, AA, Ramos, MJM, Maceiras-Pan, FJ, Díaz-Castroverde, S, García, JR, Muñoz-Fernández, S, Tasende, JAP. 01/09/2024

    PERSISTENCE OF SEQUENCING GUSELKUMAB OR TNFI AS A SECOND-LINE THERAPY FOR THE TREAT-MENT OF ACTIVE PSORIATIC ARTHRITIS IN REAL WORLD PRACTICE IN SPAIN - MANHATTAN STUDY

    Diaz, LM, Molina, RG, Huertas, CM, Joven-Ibanez, B, Fernandez-Nebro, A, Casares, EG, Soria, LM, del Rio, AH, Blanco-Morales, EA, Calzada, JM, Lizarzaburu, MS, Vilamajo, IR, Perez, ECC, Hernandez-Hernandez,, Oreiro, SC, Arana, AU, Palacio, LO, Esteban, JC, Gonzalez, RV, Alcazar, OC, Moreno-Gil, MP, Diez, AA, Ramos, MPM, Maceiras-Pan, FJ, Diaz-Castroverde, S, Garcia, JR, Munoz-Fernandez, S, Tasende, JP. 01/09/2024

    Tumoral periprostatic adipose tissue exovesicles-derived miR-20a-5p regulates prostate cancer cell proliferation and inflammation through the RORA gene

    Sánchez-Martin, S, Altuna-Coy, A, Arreaza-Gil, V, Bernal-Escoté, X, Fontgivell, JFG, Ascaso-Til, H, Segarra-Tomás, J, Ruiz-Plazas, X, Chacón, MR. 15/07/2024

    PERSISTENCE OF SEQUENCING GUSELKUMAB OR TNFI AS A SECOND-LINE THERAPY FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN REAL WORLD PRACTICE IN SPAIN - MANHATTAN STUDY

    Díaz, LM, Molina, RG, Huertas, CM, Joven-Ibáñez, B, Fernández-Nebro, A, Casares, EG, Soria, LM, del Río, AH, Blanco-Morales, EA, Calzada, JM, Lizarzaburu, MS, Vilamajó, IR, Pérez, ECC, Hernández-Hernández,, Oreiro, SC, Arana, AU, Palacio, LO, Esteban, JAC, González, RV, Alcázar, OC, Moreno-Gil, MP, Díez, AA, Moreno, RMJ, Maceiras-Pan, FJ, Diaz-Castroverde, S, García, JR, Muñoz-Fernández, S, Pinto, TJA. 01/01/2024

    In silico analysis of prognostic and diagnostic significance of target genes from prostate cancer cell lines derived exomicroRNAs

    Altuna-Coy, A, Ruiz-Plazas, X, Arreaza-Gil, V, Segarra-Tomás, J, Chacón, MR. 17/11/2023

    A serum metabolic biomarker panel for early rheumatoid arthritis

    Rodríguez-Muguruza, S, Altuna-Coy, A, Arreaza-Gil, V, Mendieta-Homs, M, Castro-Oreiro, S, Poveda-Elices, MJ, del Castillo-Piñol, N, Fontova-Garrofé, R, Chacón, MR. 01/09/2023

    A Diagnostic Accuracy Study of Targeted and Systematic Biopsies to Detect Clinically Significant Prostate Cancer, including a Model for the Partial Omission of Systematic Biopsies

    Morote, J, Picola, N, Muñoz-Rodriguez, J, Paesano, N, Ruiz-Plazas, X, Muñoz-Rivero, MV, Celma, A, Manuel, GGD, Aisian, I, Servian, P, Abascal, JM. 01/09/2023

    Administration time effect of dietary proanthocyanidins on the metabolome of Fischer 344 rats is sex- and diet-dependent

    Arreaza-Gil, V, Palacios-Jordan, H, Romero, MD, Torres-Fuentes, C, Rodriguez, MA, Remesar, X, Fernandez-López, JA, Arola-Arnal, A. 31/07/2023

    Are magnetic resonance imaging and targeted biopsies needed in men with serum prostate-specific antigen over 10 ng/ml and an abnormal digital rectal examination?

    Morote, J, Picola, N, Paesano, N, Celma, A, Muñoz-Rodriguez, J, Asiain, I, Ruiz-Plazas, X, Muñoz-Rivreo, M, de Manuel, GG, Servian, P, Abascal, JM. 01/07/2023

    Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients

    Lejeune, M, Reverté, L, Gallardo, N, Sauras, E, Bosch, R, Mata, D, Roso, A, Petit, A, Peg, V, Riu, F, Garcia-Fontgivell, J, Relea, F, Vieites, B, de la Cruz-merino, L, Arenas, M, Rodriguez, V, Galera, J, Korzynska, A, Plancoulaine, B, Alvaro, T, López, C. 01/07/2023

    Gut Microbiota Influences the Photoperiod Effects on Proanthocyanidins Bioavailability in Diet-Induced Obese Rats

    Arreaza-Gil, V, Escobar-Martínez, I, Mulero, M, Muguerza, B, Suárez, M, Arola-Arnal, A, Torres-Fuentes, C. 11/03/2023

    Photoperiod Conditions Modulate Serum Oxylipins Levels in Healthy and Obese Rats: Impact of Proanthocyanidins and Gut Microbiota

    Arreaza-Gil, V, Avila-Román, J, Escobar-Martínez, I, Muguerza, B, Suárez, M, Arola-Arnal, A, Torres-Fuentes, C. 01/02/2023

    En-bloc extended pelvic lymph node dissection during robot-assisted radical prostatectomy: A step-by-step description of the Aalst technique

    Mottaran, A, Sarchi, L, Paciotti, M, Bravi, CA, Piro, A, Nocera, L, Dominguez, J, Lores, MP, D’hondt, F, De Naeyer, G, Mottrie, A, De Groote, R. 01/02/2023

    Are we improving rates of pentafecta achievement after robot-assisted partial nephrectomy? A single high-volume institution experience over more than a decade

    Nocera, L, Bravi, CA, Balestrazzi, E, Paciotti, M, Piro, A, Peraire, LM, Sarchi, L, Mottaran, A, Piramide, F, De, GR, De, NG, Mottrie, A. 01/02/2023

    Step-by-step description of robot-assisted radical prostatectomy with the novel HUGO RAS robotic system using the Aalst-Technique

    Paciotti, M, Bravi, CA, Mottaran, A, Nocera, L, Sarchi, L, Farinha, R, Piro, A, Peraire, LM, Balestrazzi, E, Piramide, F, D’Hondt, F, De Naeyer, G, De Groote, R, Mottrie, A. 01/02/2023

    Surgical outcomes of robot-assisted radical prostatectomy with the novel HUGO™ robotic system: Initial 100 cases performed at a tertiary referral robotic center

    Paciotti, M, Bravi, CA, Sarchi, L, Mottaran, A, Balestrazzi, E, Piro, A, Peraire, LM, Nocera, L, Piramide, F, De Naeyer, G, De Groote, R, D’Hondt, F, Mottrie, A. 01/02/2023

    Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response

    Lejeune, M, Reverté, L, Sauras, E, Gallardo, N, Bosch, R, Roso, A, Petit, A, Peg, V, Riu, F, García-Fontgivell, J, Ibáñez, J, Relea, F, Vieites, B, Bor, C, de la Cruz-Merino, L, Arenas, M, Rodriguez, V, Galera, J, Korzynska, A, Belhomme, P, Plancoulaine, B, Alvaro, T, López, C. 01/02/2023

    Relationship between season of the year and severity of symptoms in patients with fibromyalgia

    Castel, A, Poveda, MJ, Rodríguez-Muguruza, S, Castro, S, Fontova, R. 20/01/2023

    Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    Martín-Varillas, JL, Sanchez-Bilbao, L, Calvo-Río, V, Adán, A, Hernanz, I, Gallego-Flores, A, Beltran-Catalan, E, Castro-Oreiro, S, Fanlo, P, Martos, AG, Torre, I, Cordero-Coma, M, De Dios, JR, García-Aparicio, A, Hernández-Garfella, M, Sánchez-Andrade, A, García-Valle, A, Maiz, O, Miguélez, R, Rodríguez-Montero, S, Urruticoechea, A, Veroz, R, Conesa, A, Fernández-Carballido, C, Jovaní, V, Mondejar, JJ, González, OM, Alvarado, PM, Romero-Yuste, S, Rubio-Muñoz, P, Peña-Sainz-Pardo, E, Garijo-Bufort, M, Demetrio-Pablo, R, Hernández, JL, Blanco, R. 01/12/2022

    National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol

    Martín-Varillas, JL, Sánchez-Bilbao, L, Río, VC, Adán, A, Rodríguez, IH, Catalán, EB, Oreiro, SC, Fanlo, P, Garcia, A, Torre, I, Coma, MC, de Dios, JR, Garcia-Aparicio, A, Garfella, MH, Andrade, AS, García-Valle, A, Maiz, O, Sanchez, JRM, Montero, SR, Urruticoechea, A, Veroz, R, Conesa, A, Fernández-Carballido, C, Casano, VJ, Martinez, O, Alvarado, PM, Yuste, SR, Muñoz, PR, Sainz-Pardo, EP, Bufort, MG, Hernández, JL, Blanco, R. 01/09/2022

    Generalized congenital myofibromatosis

    Sánchez-Puigdollers, A, Pujol-Montcusí, J, Pastor-Jane, L, César-Díaz, S, Albujar, M, Garcia-Fontgivell, J, Bel, S, Mohino, N, Turegano, P, Closa, R. 01/09/2022

    The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell's metabolic crosstalk

    Altuna-Coy, A, Ruiz-Plazas, X, Sánchez-Martin, S, Ascaso-Til, H, Prados-Saavedra, M, Alves-Santiago, M, Bernal-Escoté, X, Segarra-Tomás, J, Chacón, MR. 18/08/2022

    Trajectories in early rheumatoid arthritis related fatigue over 10 years: results from the ESPOIR cohort

    Rodriguez-Muguruza, S, Combe, B, Guillemin, F, Fautrel, B, Olive, A, Marsal, S, Valero, O, Lukas, C. 01/07/2022

    CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients

    López, C, Bosch, R, Korzynska, A, García-Rojo, M, Bueno, G, García-Fontgivell, JF, González, SM, Navarro, AG, Colón, ES, Ribes, JC, Roszkowiak, L, Mata, D, Arenas, M, Gómez, J, Roso, A, Berenguer, M, Reverté-Villarroya, S, Llobera, M, Baucells, J, Lejeune, M. 01/07/2022

    FATIGUE IN RHEUMATOID ARTHRITIS: DOES PATIENT AGE INFLUENCE?

    Rodriguez-Muguruza, S, Castro, S, Poveda, MJ, Paredes, S, Taverner, D, Fontova, R. 01/06/2022

    UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS.

    Martín-Varillas, JL, Sanchez-Bilbao, L, Calvo-Río, V, Adan, A, Rodriguez, IH, Beltrán, E, Castro, S, Mateo, PF, Martos, AG, Torre-Salaberri, I, Cordero-Coma, M, Aberásturi, JDJ, García-Aparicio, A, Hernández-Garfella, M, Sanchez-Andrade, A, García-Valle, A, Miguélez, R, Maiz, O, Montero, SR, Urruticoechea-Arana, A, Gonzalez, RV, Conesa, A, Fernández-Carballido, C, Jovani, V, González, OM, Moya, P, Romero-Yuste, S, Muñoz, PR, Sainz-Pardo, EP, Bufort, MG, Hernández, JL, Blanco, R. 01/06/2022

    STUDY "AR-CAT INICI": MANAGEMENT OF EARLY RHEUMATOID ARTHRITIS IN CATALONIA

    Perez-Garcia, C, Aguilar, JR, Mateo, L, Gomez-Puerta, JA, Roc, MV, Alarcon, GS, Morla, R, Perez, SH, Diaz-Torne, C, Lizarzaburu, MS, Gomez, CG, Castro, S, Palau, NM, Panos, HB, Minguez, S, Lasanta, ML, Ruiz-Esquide, V, Grau, CP, Busquets-Perez, N, Corominas, H, Guillen, AG, Rodriguez-Muguruza, S, Martinez-Morillo, M, Sanmartion, R. 01/06/2022

    Liquid biopsy-based exo-oncomiRNAs can predict prostate cancer aggressiveness

    Santiago, A, Plazas, R, Coy, A, Chacón, R, Tomás, S. 01/02/2022

  • Títol: PCC_07-25_AJUDES DE L'IISPV PER AL PROJECTE CIENTIFIC COMU_ DESENVOLUPAMENT D'EINES BIOANALITIQUES I COMPUTACIONALS PER A L'ESTUDI METABOLOMIC ESPACIAL DE TUMORS VESICALS: UNA APROXIMACIO INTERDISCIPLINARIA – IPV26001S

    Entitat finançadora: FUNDACIO INSTITUT D'INVESTIGACIO SANITARIA PERE I VIRGILI

    Durada: 2026-2026

    Investigador principal: RODRIGUEZ CHACON, MATILDE

  • Títol: PROGRAMA DE FONS DE PATENTS GINJOL CORRESPONENT A LA 11ª EDICIO (ANY 2022). CONVENI: 2022-11-004 – PV23050S

    Entitat finançadora: FUNDACIO INSTITUCIO DELS CENTRES DE RECERCA DE CATALUNYA

    Durada: 2023-2024

    Investigador principal: RODRIGUEZ CHACON, MATILDE

  • Títol: 2021 SGR 00870 GRUPO DE RECERCA CONSOLIDAT (GRC) OPICIO REONEIXEMENT SENSE FINANÇAMENT (VALIDACIO TECNICA) IISPV – PV23056S

    Entitat finançadora: AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA

    Durada: 2022-2025

    Investigador principal: RODRIGUEZ CHACON, MATILDE

  • Títol: PRYES246650RODR AECC NUEVO ABORDAJE PARA EL DESARROLLO DE UNA FIRMA GENETICA DE DIAGNOSTICO Y PRONOSTICO DEL CANCER DE PROSTATA BASADO EN EL IMPACTO FISIOPATOLOGICO DE LAS VESICULAS SECRETADAS POR TEJIDO ADIPOSO PERIPROSTATICO TUMORAL-PROYECTOS ESTRATEGICOS AECC2024 – PV24097S

    Entitat finançadora: FUNDACION CIENTIFICA DE LA AECC

    Durada: 2024-2027

    Investigador principal: RODRIGUEZ CHACON, MATILDE

  • Títol: CONVENIO ENTRE IISPV Y FUND. UROLOGIA ;XXXV EDICION DE BECAS Y AYUDAS DE INVESTIGACION_AYUDA DE INVESTIGACION 'PEDRO CIFUENTES DIAZ'_DESARROLLO DE UNA FIRMA MOLECULAR DERIVADA DE VESICULAS EXTRACELULARES DE SUERO PARA PREDECIR LA RESPUESTA AL TRATAMIENTO EN PACIENTES CON CANCER DE PROSTATA HORMONOSENSIBLE METASTASICO – PV26011S

    Entitat finançadora: FUNDACION PARA LA INVESTIGACION EN UROLOGIA

    Durada: 2026-2027

    Investigador principal: RUIZ PLAZAS , XAVIER

  • Títol: DONACIO_ACMB: EVALUACION DEL PANEL EXOMIR-451A, EXOMIR-25-3P, YWHAB Y STWEAK EN SUERO COMO BIOMARCADORES PARA EL DIAGNOSTICO TEMPRANO Y LA EVOLUCION DE LA ARTRITIS REUMATOIDE. – PV26042S

    Entitat finançadora: FUNDACIO PRIVADA ACADEMIA CMSCB

    Durada: 2026-2028

    Investigador principal: RODRIGUEZ MUGURUZA , SAMANTA LUCIA

  • Títol: PID2025-169175OB-I00_PROYECTOS DE GENERACION DE CONOCIMIENTO 2025_FIRMA MOLECULAR BASADA EN VESICULAS EXTRACELULARES PARA LA ESTRATIFICACION TERAPEUTICA EN CANCER DE PROSTATA METASTASICO. DESARROLLO,VALIDACION Y MECANISMOS ASOCIADOS (FMVESCAPMET) – PV26069S

    Entitat finançadora: AGENCIA ESTATAL DE INVESTIGACION

    Durada: 2026-2029

    Investigador principal: RODRIGUEZ CHACON, MATILDE

  • Títol: PREP2025_PID2025-169175OB-I00_PROYECTOS DE GENERACION DE CONOCIMIENTO Y ACTUACIONES PARA LA FORMACION DEL PERSONAL INVESTIGADOR PREDOCTORAL 2025_ – PV26070S

    Entitat finançadora: AGENCIA ESTATAL DE INVESTIGACION

    Durada: 2026-2030

    Investigador principal: RODRIGUEZ CHACON, MATILDE

  • Hospital Universitari de Tarragona Joan XXIII

    Edifici modular de Docència i Recerca

    C/ Dr. Mallafrè Guasch, 4

    43005 Tarragona

    Telèfon Contacte: 977295800 ext.3003-113

    Email Contacte: matilde.rodriguez@iispv.cat ; mrch2424@gmail.com

    veure google maps

Membres De L’equip